|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tang ZY: Hepatocellular carcinoma – cause,
treatment and metastasis. World J Gastroenterol. 7:445–454.
2001.
|
|
4
|
Bruix J and Sherman M: American
association for the study of liver diseases: management of
hepatocellular carcinoma: an update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abbotts R and Madhusudan S: Human AP
endonuclease 1 (APE1): from mechanistic insights to druggable
target in cancer. Cancer Treat Rev. 36:425–435. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kelley MR, Cheng L, Foster R, Tritt R,
Jiang J, Broshears J and Koch M: Elevated and altered expression of
the multifunctional DNA base excision repair and redox enzyme
Ape1/ref-1 in prostate cancer. Clin Cancer Res. 7:824–830.
2001.PubMed/NCBI
|
|
7
|
Yoo DG, Song YJ, Cho EJ, Lee SK, Park JB,
Yu JH, Lim SP, Kim JM and Jeon BH: Alteration of APE1/ref-1
expression in non-small cell lung cancer: the implications of
impaired extracellular superoxide dismutase and catalase
antioxidant systems. Lung Cancer. 60:277–284. 2008. View Article : Google Scholar
|
|
8
|
Xiang DB, Chen ZT, Wang D, Li MX, Xie JY,
Zhang YS, Qing Y, Li ZP and Xie J: Chimeric adenoviral vector
Ad5/F35-mediated APE1 siRNA enhances sensitivity of human
colorectal cancer cells to radiotherapy in vitro and in vivo.
Cancer Gene Ther. 15:625–635. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tanner B, Grimme S, Schiffer I,
Heimerdinger C, Schmidt M, Dutkowski P, Neubert S, Oesch F, Franzen
A, Kölbl H, et al: Nuclear expression of apurinic/apyrimidinic
endonuclease increases with progression of ovarian carcinomas.
Gynecol Oncol. 92:568–577. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Herring CJ, West CM, Wilks DP, Davidson
SE, Hunter RD, Berry P, Forster G, MacKinnon J, Rafferty JA, Elder
RH, et al: Levels of the DNA repair enzyme human
apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are
associated with the intrinsic radiosensitivity of cervical cancers.
Br J Cancer. 78:1128–1133. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang D, Luo M and Kelley MR: Human
apurinic endonuclease 1 (APE1) expression and prognostic
significance in osteosarcoma: Enhanced sensitivity of osteosarcoma
to DNA damaging agents using silencing RNA APE1 expression
inhibition. Mol Cancer Ther. 3:679–686. 2004.PubMed/NCBI
|
|
12
|
Cun Y, Dai N, Xiong C, Li M, Sui J, Qian
C, Li Z and Wang D: Silencing of APE1 enhances sensitivity of human
hepatocellular carcinoma cells to radiotherapy in vitro and in a
xenograft model. PLoS One. 8:e553132013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tell G, Quadrifoglio F, Tiribelli C and
Kelley MR: The many functions of APE1/Ref-1: not only a DNA repair
enzyme. Antioxid Redox Signal. 11:601–620. 2009. View Article : Google Scholar
|
|
14
|
Bhakat KK, Mantha AK and Mitra S:
Transcriptional regulatory functions of mammalian AP-endonuclease
(APE1/Ref-1), an essential multifunctional protein. Antioxid Redox
Signal. 11:621–638. 2009. View Article : Google Scholar
|
|
15
|
Li M and Wilson DM III: Human
apurinic/apyrimidinic endo-nuclease 1. Antioxid Redox Signal.
20:678–707. 2014. View Article : Google Scholar :
|
|
16
|
Di Maso V, Avellini C, Crocè LS, Rosso N,
Quadrifoglio F, Cesaratto L, Codarin E, Bedogni G, Beltrami CA,
Tell G, et al: Subcellular localization of APE1/Ref-1 in human
hepatocellular carcinoma: possible prognostic significance. Mol
Med. 13:89–96. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang QH, Xiang DB, Li MX, Liao PL, Li ZP
and Wang D: Expression of DNA repair gene apurinic/apyrimidinic
endonuclease 1 and its correlation with the expression of mutant
p53 in hepatocellular carcinoma. Chin J Dig Surg. 8:453–456.
2009.
|
|
18
|
Huang AM, Zheng ZH, Liu JF, Zang SB, Gao
LY and Chen SP: The expression of APE1 gene and its clinical
implication in hepatocellular carcinoma: a study using tissue chip
assay. Zhonghua Gan Zang Bing Za Zhi. 16:542–543. 2008.In Chinese.
PubMed/NCBI
|
|
19
|
Li YJ, Zheng ZH, Liu JF, Gao MQ and Huang
AM: Construction and identification of a lentiviral vector for RNA
interference of APE1 gene. J Fujian Med Univ. 44:86–90. 2010.
|
|
20
|
Casey RC, Oegema TR Jr, Skubitz KM,
Pambuccian SE, Grindle SM and Skubitz AP: Cell membrane
glycosylation mediates the adhesion, migration, and invasion of
ovarian carcinoma cells. Clin Exp Metastasis. 20:143–152. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fischer AH, Jacobson KA, Rose J and Zeller
R: Hematoxylin and eosin staining of tissue and cell sections. CSH
Prot. 2008:pdb.prot4986. 2008.
|
|
22
|
Di Maio M, De Maio E, Perrone F, Pignata S
and Daniele B: Hepatocellular carcinoma: systemic treatments. J
Clin Gastroenterol. 35(Suppl 2): S109–S114. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: SHARP investigators study group: sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Llovet JM and Bruix J: Molecular targeted
therapies in hepato-cellular carcinoma. Hepatology. 48:1312–1327.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zou GM and Maitra A: Small-molecule
inhibitor of the AP endo-nuclease 1/REF-1 E3330 inhibits pancreatic
cancer cell growth and migration. Mol Cancer Ther. 7:2012–2021.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zou GM, Karikari C, Kabe Y, Handa H,
Anders RA and Maitra A: The APE-1/Ref-1 redox antagonist E3330
inhibits the growth of tumor endothelium and endothelial progenitor
cells: therapeutic implications in tumor angiogenesis. J Cell
Physiol. 219:209–218. 2009. View Article : Google Scholar
|
|
27
|
Morris KV and Rossi JJ:
Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene
Ther. 13:553–558. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ando K, Hirao S, Kabe Y, Ogura Y, Sato I,
Yamaguchi Y, Wada T and Handa H: A new APE1/Ref-1-dependent pathway
leading to reduction of NF-kappaB and AP-1, and activation of their
DNA-binding activity. Nucleic Acids Res. 36:4327–4336. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eferl R and Wagner EF: AP-1: a
double-edged sword in tumorigenesis. Nat Rev Cancer. 3:859–868.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu P, Kimmoun E, Legrand A, Sauvanet A,
Degott C, Lardeux B and Bernuau D: Activation of NF-kappa B, AP-1
and STAT transcription factors is a frequent and early event in
human hepa-tocellular carcinomas. J Hepatol. 37:63–71. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yuen MF, Wu PC, Lai VC, Lau JY and Lai CL:
Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma.
Cancer. 91:106–112. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ozanne BW, McGarry L, Spence HJ, Johnston
I, Winnie J, Meagher L and Stapleton G: Transcriptional regulation
of cell invasion: AP-1 regulation of a multigenic invasion
programme. Eur J Cancer. 36:1640–1648. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Westermarck J and Kähäri VM: Regulation of
matrix metallo-proteinase expression in tumor invasion. FASEB J.
13:781–792. 1999.PubMed/NCBI
|
|
34
|
Lam E, Kilani RT, Li Y, Tredget EE and
Ghahary A: Stratifin-induced matrix metalloproteinase-1 in
fibroblast is mediated by c-fos and p38 mitogen-activated protein
kinase activation. J Invest Dermatol. 125:230–238. 2005.PubMed/NCBI
|
|
35
|
Fishel ML and Kelley MR: The DNA base
excision repair protein Ape1/Ref-1 as a therapeutic and
chemopreventive target. Mol Aspects Med. 28:375–395. 2007.
View Article : Google Scholar : PubMed/NCBI
|
